OpGen (NASDAQ:OPGN) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGNFree Report) in a research report sent to investors on Saturday morning. The firm issued a sell rating on the medical research company’s stock.

OpGen Stock Performance

OPGN opened at $0.41 on Friday. The company has a fifty day moving average of $0.38 and a two-hundred day moving average of $0.42. OpGen has a fifty-two week low of $0.17 and a fifty-two week high of $3.84. The stock has a market capitalization of $4.11 million, a price-to-earnings ratio of -0.06 and a beta of -0.90.

OpGen (NASDAQ:OPGNGet Free Report) last released its quarterly earnings results on Tuesday, November 14th. The medical research company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). OpGen had a negative return on equity of 316.30% and a negative net margin of 852.18%. The business had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.90 million. On average, equities research analysts forecast that OpGen will post -2.02 earnings per share for the current year.

Hedge Funds Weigh In On OpGen

Large investors have recently added to or reduced their stakes in the stock. HRT Financial LP acquired a new stake in shares of OpGen in the fourth quarter valued at about $26,000. Citadel Advisors LLC boosted its holdings in OpGen by 571.0% in the 3rd quarter. Citadel Advisors LLC now owns 100,773 shares of the medical research company’s stock worth $29,000 after buying an additional 85,754 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in OpGen in the 1st quarter worth about $49,000. Finally, Vanguard Group Inc. increased its stake in OpGen by 39.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,877,597 shares of the medical research company’s stock worth $537,000 after buying an additional 534,960 shares in the last quarter. 13.07% of the stock is currently owned by institutional investors and hedge funds.

About OpGen

(Get Free Report)

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Read More

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.